CG Oncology (NASDAQ:CGON) Trading Down 8.1%

Shares of CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) traded down 8.1% on Wednesday . The stock traded as low as $30.92 and last traded at $31.20. 328,852 shares were traded during mid-day trading, a decline of 50% from the average session volume of 651,423 shares. The stock had previously closed at $33.95.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on CGON shares. The Goldman Sachs Group assumed coverage on CG Oncology in a report on Tuesday, February 20th. They issued a "neutral" rating and a $42.00 price target on the stock. HC Wainwright restated a "buy" rating and issued a $75.00 price objective on shares of CG Oncology in a research note on Monday. Morgan Stanley started coverage on shares of CG Oncology in a research report on Tuesday, February 20th. They set an "overweight" rating and a $55.00 target price for the company. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $75.00 price target on shares of CG Oncology in a research report on Thursday, May 2nd.

CG Oncology Stock Down 4.5 %

The firm's 50 day moving average price is $39.17.

Institutional Investors Weigh In On CG Oncology

Large investors have recently added to or reduced their stakes in the company. TimesSquare Capital Management LLC purchased a new position in CG Oncology during the 1st quarter valued at $9,837,000. Capstone Investment Advisors LLC bought a new position in shares of CG Oncology during the first quarter valued at $806,000. Finally, BNP Paribas Financial Markets purchased a new stake in shares of CG Oncology during the first quarter valued at $492,000. Institutional investors own 26.56% of the company's stock.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.